News Gilead, Amgen kick off facility investments in US This week saw both Gilead Sciences and Amgen start to fulfil pledges to step up capital investments in new US facilities.
News Sanofi slumps despite positive eczema drug readout Shares in Sanofi have fallen after it reported data from a phase 3 trial of atopic dermatitis drug amlitelimab – even though it met all objectives.
News Amgen's Five Prime takeover delivers gastric cancer win Four years after buying Five Prime for $1.9bn, Amgen has promising phase 3 results with a gastric cancer drug that was the focal point for the deal.
News Italfarmaco closes on EU okay for Duchenne drug Italfarmaco's oral HDAC inhibitor Duvyzat has been recommended for approval in the EU as a treatment for Duchenne muscular dystrophy (DMD).
News Cheaper Soliris biosimilars reach the US market The first biosimilars of AstraZeneca/Alexion's blockbuster complement C5 inhibitor Soliris have been launched in the US at a discount to the brand.
News Uplizna is first drug FDA-cleared for rare disease IgG4-RD Amgen has bagged a second indication for its B cell-depleting therapy Uplizna after the FDA cleared it for rare inflammatory disease IgG4-RD.
R&D The long-delayed promise of the microbiome, with Sam Possemi... Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
